Copper-Curcumin-Bipyridine Dicarboxylate Complexes As Anticancer Candidates Publisher Pubmed

Summary: Scientists report copper-curcumin complexes kill breast cancer cells effectively while safe for normal cells, promising new treatments. #CancerResearch #NaturalCompounds

Emami F¹ ; Aliomrani M² ; Tangestaninejad S³ ; Kazemian H^{4, 5} ; Moradi M¹ ; Rostami M¹
Source: Chemistry and Biodiversity Published:2022

Abstract

In this study, copper complexes with Curcumin (Cur) and 2,2’-bipyridine-5,5’-dicarboxylic acid (BPYD) were synthesized and their cytotoxicity on the MDA-MB-231 cell lines was evaluated. The resulting complex was characterized using FTIR, UV/VIS, CHNS, TGA, ICP-MS, and Mass spectroscopy techniques. The in-vitro cytotoxicity was studied on the MDA-MB-231 as a cancerous cell line and the HUVEC as a normal cell line. Reactive oxygen species (ROS) production was measured using the 2′,7′-dichlorofluorescein diacetate (DCFDA) test in the MDA-MB-231 cancer cell lines. The in-vitro assays revealed that all synthesized copper complexes exhibited a higher cytotoxicity effect than carboplatin as a positive control on the MDA-MB-231 cells. While the synthesized complexes exhibited cytotoxic effects on cancerous cell lines, they are practically safe on normal cells. The Cu-Cur-BPYD complexes (a5 & b5) exhibited higher cytotoxicity on MDA-MB-231 cells with IC50s around 4.9 and 2.3 mM, respectively. It can be concluded that the synthesized Cu-Cur-BPYD complexes (a5 & b5) could be considered effective anticancer candidates in complementary studies. © 2022 Wiley-VHCA AG, Zurich, Switzerland.